Vol 20, No 6 (2013)
Original articles
Published online: 2013-12-11

open access

Page views 2342
Article views/downloads 2343
Get Citation

Connect on Social Media

Connect on Social Media

Effects of age on aerobic capacity in heart failure patients under beta-blocker therapy: Possible impact in clinical decision-making?

Emmanuel Gomes Ciolac, Edimar Alcides Bocchi, Miguel Morita Fernandes da Silva, Aline Cristina Tavares, Iram Soares Teixeira-Neto, Guilherme Veiga Guimarães
DOI: 10.5603/CJ.2013.0166
Cardiol J 2013;20(6):655-661.

Abstract

Background: Heart failure (HF) is associated with impaired maximal aerobic capacity asindicated by decreases in peak oxygen uptake (peak VO2). Considering that aging by itself has a negative effect on this variable, the evaluation of maximum capacity is often questioned because current predicted peak VO2 is based on subjects without heart disease or b-blocker therapy. In contrast, if decline in predicted and attained peak VO2 were age-related, proportionally, loss ofaerobic function (predicted peak VO2, %) would remain stable over time in these patients. The purpose of this investigation is to assess the effects of age on peak VO2 in HF patients taking b-blockers.\

Methods: We retrospectively evaluated 483 (132 female) patients (aged 20–88 years, LVEF31 ± 11%) with non-ischemic (n = 362), ischemic (n = 74) and Chagas-related HF (n = 47) who had been submitted to an incremental cardiopulmonary exercise testing on a motorized treadmill. Linear regression was used to develop the equation to predict peak VO2, based on age.

Results: Peak VO2 decreased 0.9 mL/min/kg per age-decade, maximum HR also decreased with aging and VE/VCO2 slope was similar among all decades. The predicted new b-blocker equation to peak VO2 bb was 20.934 – 0.092 × age.

Conclusions: Clinical interpretation of aerobic capacity impairment is infl uenced by agingin HF patients. This evidence must be considered when using peak VO2 for prognostic stratification and clinical decision-making in patients with HF under b-blocker therapy.